idcc, what am I wrong about? Knuts mentioned R/A/RC's Nilvad trial and I provided a comment.
I know RC's anatabine is not focused on beta-amyloid. I have mentioned previously that I hope Anavex would use anatabine citrate and its anti-inflammation mechanism with Anavex's 2-73 drug ... I think that would be a real winner against AD and probably other CNS diseases.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.